$214 Million is the total value of TCG Crossover Management, LLC's 15 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ISEE | New | Iveric Bio, Inc. | $29,113,000 | – | 1,741,228 | +100.0% | 13.63% | – |
| VRDN | New | Viridian Therapeutics Inc | $25,978,000 | – | 1,314,000 | +100.0% | 12.16% | – |
| COGT | New | Cogent Biosciences, Inc. | $23,595,000 | – | 2,750,037 | +100.0% | 11.05% | – |
| CBAY | New | CYMABAY THERAPEUTICS, INC. | $19,960,000 | – | 5,905,400 | +100.0% | 9.35% | – |
| ALPN | New | Alpine Immune Sciences, Inc. | $16,207,000 | – | 1,170,212 | +100.0% | 7.59% | – |
| ACRS | New | Aclaris Therapeuitics, Inc. | $15,735,000 | – | 1,082,213 | +100.0% | 7.37% | – |
| KDNY | New | CHINOOK THERAPEUTICS, INC. | $14,391,000 | – | 882,353 | +100.0% | 6.74% | – |
| New | Tyra Biosciences, Inc. | $11,966,000 | – | 850,450 | +100.0% | 5.60% | – | |
| New | Entrada Therapeutics, Inc. | $11,362,000 | – | 663,694 | +100.0% | 5.32% | – | |
| AVTE | New | Aerovate Therapeutics, Inc. | $10,061,000 | – | 853,330 | +100.0% | 4.71% | – |
| MGTA | New | Magenta Therapeutics, Inc. | $9,844,000 | – | 2,222,222 | +100.0% | 4.61% | – |
| AKUS | New | Akouos, Inc. | $8,884,000 | – | 1,045,215 | +100.0% | 4.16% | – |
| MRUS | New | Merus N.V. | $7,155,000 | – | 225,000 | +100.0% | 3.35% | – |
| ZLAB | New | Zai Lab Limited | $5,971,000 | – | 95,000 | +100.0% | 2.80% | – |
| ELEV | New | Elevation Oncology, Inc. | $3,341,000 | – | 555,000 | +100.0% | 1.56% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COGENT BIOSCIENCES INC | 8 | Q3 2023 | 15.6% |
| AEROVATE THERAPEUTICS INC | 8 | Q3 2023 | 6.5% |
| TYRA BIOSCIENCES INC | 8 | Q3 2023 | 6.2% |
| ENTRADA THERAPEUTICS INC | 8 | Q3 2023 | 5.3% |
| MERUS N.V. | 8 | Q3 2023 | 3.4% |
| IVERIC BIO INC | 7 | Q2 2023 | 24.4% |
| Geron Corporation | 7 | Q3 2023 | 12.4% |
| ACLARIS THERAPEUTICS INC | 7 | Q2 2023 | 7.9% |
| KURA ONCOLOGY INC | 7 | Q3 2023 | 9.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q2 2023 | 7.6% |
View TCG Crossover Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Silence Therapeutics plc | August 19, 2022 | 6,314,625 | 5.9% |
| CymaBay Therapeutics, Inc. | November 29, 2021 | 5,905,400 | 7.0% |
| Cogent Biosciences, Inc. | November 17, 2021 | 2,716,042 | 6.8% |
| Tyra Biosciences, Inc. | September 29, 2021 | 937,500 | 2.2% |
| Viridian Therapeutics, Inc.\DE | September 29, 2021 | 1,314,000 | 8.2% |
View TCG Crossover Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| SC 13G | 2022-08-19 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-18 |
View TCG Crossover Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.